Cargando…
The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine
BACKGROUND: Brain metastases (BM) represent the most frequent intracranial tumors with increasing incidence. Many primary tumors are currently treated in protocols that incorporate targeted therapies either upfront or for progressive metastatic disease. Hence, molecular markers are gaining increasin...
Autores principales: | Katzendobler, Sophie, Do, Anna, Weller, Jonathan, Rejeski, Kai, Dorostkar, Mario M., Albert, Nathalie L., Forbrig, Robert, Niyazi, Maximilian, Egensperger, Rupert, Tonn, Joerg-Christian, von Baumgarten, Louisa, Quach, Stefanie, Thon, Niklas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808072/ https://www.ncbi.nlm.nih.gov/pubmed/36605448 http://dx.doi.org/10.3389/fonc.2022.1014711 |
Ejemplares similares
-
Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas
por: Katzendobler, Sophie, et al.
Publicado: (2022) -
Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
por: Weller, Jonathan, et al.
Publicado: (2022) -
Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers
por: Karschnia, Philipp, et al.
Publicado: (2021) -
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression
por: Weller, Jonathan, et al.
Publicado: (2021) -
Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status
por: Weller, Jonathan, et al.
Publicado: (2023)